INI1 Negative Malignant Tumors (With PI Approval) clinical trials at UCSF

1 research study open to eligible people

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 30 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations

Our lead scientists for INI1 Negative Malignant Tumors (With PI Approval) research studies include Alyssa Reddy.

Last updated: July 14, 2022

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers